Cargando…

Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults

OBJECTIVE: We evaluated safety, antiviral, immunomodulatory and anti-inflammatory properties of aprepitant – a neurokinin 1 receptor antagonist. DESIGN: Phase IB randomized, placebo-controlled, double-blinded study. METHODS: Eighteen patients were randomized (nine to aprepitant and nine to placebo)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Tebas, Pablo, Spitsin, Sergei, Barrett, Jeffrey S., Tuluc, Florin, Elci, Okan, Korelitz, James J., Wagner, Wayne, Winters, Angela, Kim, Deborah, Catalano, Renae, Evans, Dwight L., Douglas, Steven D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472318/ https://www.ncbi.nlm.nih.gov/pubmed/25915168 http://dx.doi.org/10.1097/QAD.0000000000000638

Ejemplares similares

A Randomized, Placebo Controlled, Double Masked Phase IB Study Evaluating the Safety and Antiviral Activity of Aprepitant, a Neurokinin-1 Receptor Antagonist in HIV-1 Infected Adults
por: Tebas, Pablo, et al.
Publicado: (2011)

Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV
por: Barrett, Jeffrey S., et al.
Publicado: (2016)

Effect of aprepitant on kynurenine to tryptophan ratio in cART treated and cART naïve adults living with HIV
por: Spitsin, Sergei, et al.
Publicado: (2021)

Soluble ectodomain CD163 and extracellular vesicle-associated CD163 are two differently regulated forms of ‘soluble CD163’ in plasma
por: Etzerodt, Anders, et al.
Publicado: (2017)

Design and Characterization of Phosphatidylcholine-Based Solid Dispersions of Aprepitant for Enhanced Solubility and Dissolution
por: Yeo, Sooho, et al.
Publicado: (2020)

Soluble CD 163: A novel biomarker
por: Ahuja, Rajeev B.
Publicado: (2011)

Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography
por: Chen, Shuanghong, et al.
Publicado: (2019)

Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy
por: Ständer, Sonja, et al.
Publicado: (2010)

The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
por: Muñoz, Miguel, et al.
Publicado: (2020)

Soluble CD163 was linked to galectin-3, diabetic retinopathy and antidepressants in type 1 diabetes
por: Melin, Eva O, et al.
Publicado: (2018)

Local production of soluble CD163 in the spondyloarthropathic joint
por: Baeten, D, et al.
Publicado: (2003)

Soluble CD163 correlates with lipid metabolic adaptations in type 1 diabetes patients during ketoacidosis
por: Svart, Mads, et al.
Publicado: (2018)

Soluble Levels of CD163, PD-L1, and IL-10 in Renal Cell Carcinoma Patients
por: Davidsson, Sabina, et al.
Publicado: (2022)

Quantification of Central Substance P Receptor Occupancy by Aprepitant Using Small Animal Positron Emission Tomography
por: Endo, Tadashi, et al.
Publicado: (2015)

Soluble CD163 as a Potential Biomarker in Systemic Sclerosis
por: Frantz, Camelia, et al.
Publicado: (2018)

Soluble CD163 in intracerebral hemorrhage: biomarker for perihematomal edema
por: Roy‐O'Reilly, Meaghan, et al.
Publicado: (2017)

The interaction of ifosfamide and aprepitant in gynecologic malignancies()
por: Shindorf, Mackenzie L., et al.
Publicado: (2013)

Aprepitant for the Treatment of Chronic Refractory Pruritus
por: He, Alice, et al.
Publicado: (2017)

Clinical Significance of Soluble Hemoglobin Scavenger Receptor CD163 (sCD163) in Sepsis, a Prospective Study
por: Feng, Lin, et al.
Publicado: (2012)

Soluble CD163 and CD163 Expression on Monocytes Associated with Chronic Hepatitis B Inflammation and HBsAg Loss
por: Xie, Peilin, et al.
Publicado: (2022)

Aprepitant inhibits the progression of esophageal squamous cancer by blocking the truncated neurokinin‑1 receptor
por: Zheng, Yang, et al.
Publicado: (2023)

Soluble CD163-Associated Dietary Patterns and the Risk of Metabolic Syndrome
por: Hu, Tzu-Yu, et al.
Publicado: (2019)

Utility of Soluble CD163 in the Clinical Management of Patients With Kawasaki Disease
por: Azuma, Yoshihiro, et al.
Publicado: (2020)

Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis
por: Zhang, Yue, et al.
Publicado: (2021)

GPCR large-amplitude dynamics by (19)F-NMR of aprepitant bound to the neurokinin 1 receptor
por: Pan, Benxun, et al.
Publicado: (2022)

The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant
por: Coveñas, Rafael, et al.
Publicado: (2023)

Treatment for Refractory Pruritus Using Oral Aprepitant
por: Huh, Joon Won, et al.
Publicado: (2016)

Aprepitant for the management of nausea with inpatient IV dihydroergotamine
por: Chou, Denise E., et al.
Publicado: (2016)

Emerging Role of Aprepitant in Cannabis Hyperemesis Syndrome
por: Parvataneni, Swetha, et al.
Publicado: (2019)

In Vitro Evaluation of a Solid Supersaturated Self Nanoemulsifying Drug Delivery System (Super-SNEDDS) of Aprepitant for Enhanced Solubility
por: Nazlı, Hakan, et al.
Publicado: (2021)

Soluble CD163 and glycated haemoglobin were independently associated with the progression of diabetic retinopathy in adult patients with type 1 diabetes
por: Hector, Sven, et al.
Publicado: (2023)

Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting
por: Lim, Chae Seong, et al.
Publicado: (2013)

Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis
por: Gantzel, Rasmus Hvidbjerg, et al.
Publicado: (2021)

Soluble CD163 Identifies Those at Risk for Increased Hepatic Inflammation & Fibrosis
por: Sherman, Kenneth E, et al.
Publicado: (2021)

Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors
por: Halik, Paweł K., et al.
Publicado: (2020)

The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis
por: Alsaeed, Mohammed Ali, et al.
Publicado: (2022)

Precision hfs of $^{126}$Cs(T$_{1/2}$=1.63m) by ABMR
por: Pinard, J, et al.
Publicado: (2003)

Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant
por: Olver, Ian, et al.
Publicado: (2007)

Preparation and Characterization of Nanosuspension of Aprepitant by H96 Process
por: Kalvakuntla, Sunethra, et al.
Publicado: (2016)

Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits
por: Kura, Raghunandan Reddy, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f0u06l8halai013eg9u5vu8kh2